MRK · News · 20261102N

Oncology Pipeline Progress

Merck & Co., Inc. · 2026-11-02 · Importance 39 · Surprise 42

Moderna’s personalized mRNA cancer vaccine intismeran, developed with Merck, is being tested in combination with Keytruda. The report says the combination significantly reduced the risk of recurrence or death in melanoma patients, while overall-survival data and regulatory approval remain pending. Personalized manufacturing logistics are also identified as a challenge for the vaccine’s potential commercialization.

Key facts

• Intismeran combined with Keytruda significantly reduced the risk of recurrence or death in melanoma patients. source
• Merck developed intismeran, a personalized mRNA cancer vaccine, with Moderna. source
• Overall-survival data and regulatory approval for the personalized cancer vaccine remain pending. source